These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36139377)

  • 1. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
    Miao YR; Liu CJ; Hu H; Yang M; Guo AY
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
    Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
    Oncologist; 2024 Jul; 29(7):619-628. PubMed ID: 38655867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
    Lim SY; da Silva IP; Adegoke NA; Lo SN; Menzies AM; Carlino MS; Scolyer RA; Long GV; Lee JH; Rizos H
    Mol Cancer; 2024 Oct; 23(1):228. PubMed ID: 39394099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
    Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
    Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
    Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
    Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.
    Moeckel C; Bakhl K; Georgakopoulos-Soares I; Zaravinos A
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Pinato DJ; Urus H; Newsom-Davis T; Du Parcq P; Belessiotis K; Mapara L; Gupta N; Power D; Weir J; Wong CN; Ratnakumaran RP; Dominy K; Khorashad J; Bower M
    J Immunother; 2020; 43(2):53-56. PubMed ID: 31567705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.
    Patterson A; Auslander N
    Nat Commun; 2022 Sep; 13(1):5151. PubMed ID: 36123351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response.
    Weir WH; Mucha PJ; Kim WY
    Cell Rep Med; 2022 May; 3(5):100602. PubMed ID: 35584624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
    Onieva JL; Xiao Q; Berciano-Guerrero MÁ; Laborda-Illanes A; de Andrea C; Chaves P; Piñeiro P; Garrido-Aranda A; Gallego E; Sojo B; Gálvez L; Chica-Parrado R; Prieto D; Pérez-Ruiz E; Farngren A; Lozano MJ; Álvarez M; Jiménez P; Sánchez-Muñoz A; Oliver J; Cobo M; Alba E; Barragán I
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
    Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
    Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
    Anagnostou V; Niknafs N; Marrone K; Bruhm DC; White JR; Naidoo J; Hummelink K; Monkhorst K; Lalezari F; Lanis M; Rosner S; Reuss JE; Smith KN; Adleff V; Rodgers K; Belcaid Z; Rhymee L; Levy B; Feliciano J; Hann CL; Ettinger DS; Georgiades C; Verde F; Illei P; Li QK; Baras AS; Gabrielson E; Brock MV; Karchin R; Pardoll DM; Baylin SB; Brahmer JR; Scharpf RB; Forde PM; Velculescu VE
    Nat Cancer; 2020 Jan; 1(1):99-111. PubMed ID: 32984843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.